On Aug. 15, 2019, the Cancer Prevention and Research Institute of Texas (CPRIT) announced that it was awarded a New Company Product Development award to Salarius Pharmaceuticals, a clinical-stage oncology company.

Salarius, a clinical-stage oncology company, was the recipient of a 3-year $18.7 million CPRIT New Company Product Development award, who recently announced it enrolled the first patient in a Phase 1 clinical study targeting this cancer.

Ewing’s Sarcoma is a rare and devastating bone and soft-tissue cancer that mostly afflicts children and young adults for which no approved targeted therapies are currently available.